CannabisNewsBreaks – AgraFlora Organics International Inc. (CSE: AGRA) (Frankfurt: PU31) (OTC: AGFAF) Receives UK Home Office Controlled Drug License

January 24, 2020 11:34:09

AgraFlora Organics International (CSE: AGRA) (Frankfurt: PU31) (OTC: AGFAF), a growth oriented and diversified international cannabis company, yesterday announced that Farmako GmbH, through its wholly owned subsidiary Farmako Limited has received its Home Office Controlled Drug License. According to the update, Farmako Limited was awarded the License less than one month following the successful completion of its inspection by the UK Home Office in December 2019. With the License, Farmako Limited plans to commence wholesaling medical cannabis in the UK by mid-year 2020, including importation of Bedrocan products to the UK from the Netherlands for patient distribution. “The UK medicinal cannabis market has been estimated to reach US$1.3 billion by 2024, with up to 1% of the UK’s population expected to be eligible to receive medicinal cannabis prescriptions by 2028,” Farmako CEO Katrin Eckmans said in the news release ( “Obtaining the License is a key milestone for our European business, positioning Farmako Limited as an early leader in the rapidly developing UK medicinal cannabis market.”

To view the full press release, visit

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice (“GMP”) edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit:

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.